Aquestive Therapeutics forecasts 2026 revenue USD 46 million-50 million - AQST News | RalliesAquestive Therapeutics forecasts 2026 revenue USD 46 million-50 million
A
AQST• 2026 guidance and cash position
- Aquestive Therapeutics guided 2026 total revenue of about USD 46 million to USD 50 million.
- The company forecast a non-GAAP adjusted EBITDA loss of about USD 35 million to USD 30 million.
- Q2 2026 ended with about USD 98.5 million in cash and cash equivalents.
- It expects USD 75 million from the RTW Strategic Funding Agreement upon Anaphylm approval.
- It also anticipates USD 20 million in additional debt financing from Oak Tree upon Anaphylm approval.
•
